The LRF Research Program: Impact

The Lymphoma Research Foundation's (LRF) Research Program is dedicated to overcoming lymphoma and making a difference for people affected by the disease. LRF has provided leadership and support, advancing lymphoma research from multiple directions since 1992. In that time, the Foundation has:


  • More than $50 million to understand, treat and cure lymphoma.
  • Over 300 grants.
  • Senior researcher awards to advance our understanding and ability to treat chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma.
  • Fellowships to develop junior researchers and study important questions in lymphoma.
  • Clinical Career Development Awards to help train physicians to carry out significant clinical research studies.


  • The development of over 180 young investigators, who are now working to improve our knowledge and treatment of lymphoma.
  • Researchers at 100 leading cancer research centers and academic medical centers.
  • Investigations into mantle cell lymphoma (MCL), a rare form of lymphoma not well understood before LRF started its MCL Initiative and Consortium.
  • Scientific workshops for investigators to share their work, build collaborations, and tackle important questions.


  • Our understanding of lymphoma, especially regarding lymphoma's molecular and genetic basis, which is fundamental to the development of targeted therapeutics.
  • Our disease focus area strategy adding additional programs as funds become available, funding grants in CLL/SLL, Follicular Lymphoma and DLBCL.
  • The MCL Cell Bank, a resource important to studying questions such as the effectiveness of experimental therapeutics.


LRF funded researchers have made major contributions to our understanding and treatment of lymphoma, for example:

  • Enhanced understanding of genes involved in the development of follicular lymphoma.
  • Improved understanding of potential CLL targets.
  • Advanced gene expression profiling, with the creation of a novel "Five Gene Model" for MCL, which helps to predict a patient's prognosis and helps to tailor treatments.
  • Furthered understanding of new molecular targets such as the heat shock protein (HSP).
  • Progressed toward development of a promising gene-therapy approach for follicular lymphoma.

Learn more about LRF's Research Program, the strategy and leadership behind our research portfolio or read the latest edition of Research Report, the Foundation's premier research publication.